Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: ataluren, zolimomab aritox, elx-02 +2 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 103 | 0.91 |
| pathways Reactome | 21 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 9051
Sealed predictions
- RPS17 in dopamine neurons, braak+0.45 (p 0.230) → -0.86 (p 0.003)receipt 9058
Swarm cases
receipt 9058: RPS17 in dopamine neurons, braak
- power
- full sample -0.30 (p 0.228, n 18), 95% CI -0.67 to +0.20. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.35 (p 0.150, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.43 (p 0.079, n 18). could be the mix.
- skeptic
- leave-one-out range -0.41 to -0.21, sign flips 0; without severely affected donors -0.30 (p 0.228, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RPS17 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts